文献速递胸部肿瘤放疗放疗物理与技术

CURE Lung多中心再程放疗试验治疗计划方案的制定

Development of a treatment planning protocol for the multi-centre reirradiation CURE Lung trial.
PubMed 文献 · Radiother Oncol · 2025-11-19

为准备斯堪的纳维亚CURE Lung试验,通过文献回顾与实时研讨会制定肺癌高剂量再程放疗治疗计划指南。6例高剂量再程放疗病例在8个中心完成计划优化,将既往剂量映射至当前CT并以EQD2Gy(α/β=3 Gy,脊髓α/β=2 Gy)累加后集中审核,建立了一致性指南与等效累积剂量约束,并明确了危及器官约束优先于靶区覆盖的优先顺序。

要点

  • 建立了高剂量肺癌再程放疗的治疗计划指南与等效累积剂量约束。
  • 病例4显示靶区覆盖与危及器官约束冲突时需明确优先级,共识为优先满足危及器官约束。
  • 病例5和6所有中心为满足危及器官约束而降低了PTV剂量。

核心结论

  • 制定了肺癌高剂量再程放疗的治疗计划方案,并确认了所提等效累积剂量约束的可行性与依从性。

研究设计与样本

  • 通过文献回顾与实时研讨会制定治疗计划指南,并以6例高剂量再程放疗肺癌病例在8个放疗中心开展多中心治疗计划研究。

主要发现

  • 病例1-3各中心均遵守约束;病例4覆盖PTV同时满足危及器官约束困难,出现较大差异。
  • 达成优先满足危及器官约束的共识后,各中心对病例4重新优化。
  • 病例5和6所有中心为遵守危及器官约束而使PTV剂量不足,累积危及器官剂量总体差异较大。

关键数值与推荐

  • 既往治疗物理3D剂量分布映射至当前CT,既往剂量与当前剂量换算为EQD2Gy(α/β=3 Gy,脊髓α/β=2 Gy)后由各中心累加并集中审核。
  • 共识优先顺序为危及器官约束优先于靶区覆盖。

临床怎么用

  • 再程放疗计划应基于等效累积剂量约束评估危及器官受量,并在靶区覆盖与危及器官约束冲突时优先满足危及器官约束。

局限性

  • 原文未报告纳入文献数量、病例随访或临床结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: High-dose lung cancer reirradiation is promising but associated with high toxicity risk. Development of and adherence to consensus guidelines will support safe use. MATERIALS AND METHODS: Literature review and live workshops were conducted to develop treatment planning guidelines in preparation for the Scandinavian CURE Lung trial. Relevant OARs, dose metrics, constraints, and priorities were considered. For six high-dose reirradiation lung cancer cases, the physical 3D dose distribution of previous treatment was mapped to current CT. The cases were distributed to eight radiotherapy centres, which optimised plans on current CT respecting equieffective cumulative dose constraints. Mapped previous dose and current dose were rescaled to EQD2Gy (α/β = 3 Gy, spinal cord: α/β = 2 Gy), summed by each centre, and reviewed centrally. After cases 1-4 were completed, prioritisation between OAR constraints and target coverage was clarified. RESULTS: Consensus agreement on guidelines for treatment planning, equieffective cumulative dose constraints, and priorities was established. For cases 1-3, centres complied with constraints. For case 4, covering PTV while respecting OAR constraints was difficult, and major variations were identified, underscoring the need for clearer prioritisation guidance. Consensus was reached to prioritise OAR constraints, and centres re-optimised case 4 accordingly. For cases 5 and 6, all centres underdosed PTV, to comply with OAR constraints. Generally, considerable variation in cumulative OAR doses was observed. CONCLUSIONS: A treatment planning protocol was developed. The pre-trial multi-centre treatment planning study identified and resolved key missing guidance to facilitate common conception of consensus guidelines. Feasibility and compliance with the proposed equieffective cumulative dose constraints were established.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Hoffmann L, Linaa MB, Ehmsen ML, et al. Development of a treatment planning protocol for the multi-centre reirradiation CURE Lung trial. Radiother Oncol. 2025. PMID: 41271177. doi:10.1016/j.radonc.2025.111293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。